Royalty Report: Drugs, Drug Discovery, Disease – Collection: 240565

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Drug Discovery
  • Disease
  • Therapeutic
  • Bacterial Infection
  • Diagnostic
  • Content
  • Proteins
  • Medical Info
  • Data Management
  • Assay

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 240565

License Grant
Licensor grants to Licensee (i) a worldwide exclusive license, with the right to sublicense, under Exclusive Research Program Patents and Exclusive Research Program Technology to conduct research and development with respect to, and to make, have made, use, sell, offer to sell and import Product for use in the Product Field;  (ii) a worldwide non-exclusive license, with the right to sublicense, under Licensor Research Program Patents, Licensor Research Program Technology, Licensor Technology and Licensor Patents to make and have made Product, in research quantities as permitted, and under then-current GMP conditions to support the clinical program and for commercialization of such Product.

Licensor hereby grants to Licensee a non-exclusive, worldwide, royalty-free license, with the right to grant sublicenses to the third party contractors, to use the Screening Libraries in the Screening Field to conduct the Research Program in accordance with this Agreement.

License Property
Product means a product that is or includes a compound within an Identified Compound Family(s) in all formulations and for all uses.

Screening Product means a Product for use as an anti-bacterial agent or anti-fungal agent in each case in the Product Field.

Identified Compound Family means an Identified Compound and all analogs, homologs, derivatives and congeners thereof as determined by the Research Committee according to the procedure set forth, and mutually agreed to in writing by both parties.

Identified Compound(s) means (i) a compound(s) that has Activity against a Target, (ii) that is obtained from a Screening Library and (iii) the chemical structure of which Licensee requests in writing that Licensor identify pursuant to this Agreement.

Exclusive Research Program Patents means all patents and patent applications, both foreign and domestic, including, without limitation, provisionals, converted provisionals, continuations, divisionals or continuations in part, (i) covering Exclusive Research Program Technology; or (ii) that claim methods of making or isolating a compound(s) within an Identified Compound Family, provided that such claimed method of making or isolating is limited only to such compound(s).

Exclusive Research Program Technology means all information, know-how, trade secrets, inventions and data made during the course of the parties’ performance under the Research Program that are directed to a composition, formulation or use of a compound within an Identified Compound Family.  Exclusive Research Program Technology does not include information, know-how, trade secrets, inventions or data applicable to methods of making, separating, or purifying compounds within an Identified Compound Family.

Field of Use
Product Field means any diagnostic, preventive or therapeutic application.  Screening Field means the identification of compounds having anti-bacterial or anti-fungal properties.

IPSCIO Record ID: 227289

License Grant
The parties agree to collaborate with each other relating to the discovery and optimization of compounds for use in the Field with respect to certain biological targets within the Field.

Screening License – Licensor hereby grants to Licensee a nonexclusive, worldwide, royalty-free license (without the right to sublicense) under the Licensor Patent Rights and other rights in the Licensor Technology to screen Licensor Compounds delivered under the collaboration against Anti-Infective Targets and Anti-Fungal Targets in the Field, but only during the Screening Phase.

Develop and Commercialize License – Licensor hereby grants to Licensee and its Affiliates the following licenses

         (i)      an exclusive, worldwide license (with the right to sublicense) under the Licensor Patent Rights and other rights in Licensor Technology to conduct development of Licensed Compounds in the Field, including the right to develop Analog Compounds based on Licensed Compounds.;
         (ii)     an exclusive, worldwide license (with the right to sublicense) under the Licensor Patent Rights and other rights in Licensor Technology to make, have made, use, have used, sell, and import Licensed Compounds and certain identified Analog Compounds, as described below, in the Field; and
         (iii)    a non-exclusive, worldwide license (with the right to sublicense) under the Licensor Patent Rights and other rights in Licensor Technology to use chemical synthesis methods within the Licensor Patent Rights and Licensor Technology to make and have made Royalty-Bearing Products.

License Property
Licensor Compound means a chemical compound owned or controlled by Licensor provided by Licensor to Licensee pursuant to this Agreement as part of a screening library, including without limitation the compounds provided in the Compass Array Library and Mapping Array Libraries.

Licensed Compound Se means a set of one or more Licensed Compounds from the same Mapping Array Library that have biological activity for the same Target, as well as any Licensor Analog Compounds of such Licensed Compounds that are synthesized by a party in the course of optimizing those Licensed Compounds.

Patent Rights means any United States and foreign patent application and any divisional, continuation, or continuation-in-part of such patent application (to the extent the claims are directed to subject matter specifically described therein), as well as any patent issued thereon and any reissue or reexamination of such patent, and any foreign counterparts to such patents and patent applications.

Field of Use
Field means all applications in the life sciences relating to human therapeutic products for the treatment, prophylaxis or diagnosis of infectious diseases caused by bacterial organisms.

IPSCIO Record ID: 239020

License Grant
This agreement is between the Licensor, the Licensee and the Institute Licensee which is a division of the Licensee.

For the Research Program, Licensor agrees to conduct the Research Program in collaboration with the Licensee Institute partner with a goal of discovering, identifying and synthesizing Licensed Compounds for Development by Institute Licensee into one or more Products for commercialization by Licensee, an Affiliate or Sublicensee.

During the Exclusive Screening Period, the Institute Licensee shall have the exclusive right to screen Macrolides provided by Licensor for Antibiotic Activity.

During the Non-exclusive screening period, the Institute Licensee and its Affiliates shall have the non-exclusive right to screen the Macrolides, for any biological activity, in any biological test system for any therapeutic indication.

During the Non-exclusive screening period, the Institute Licensee shall have a non-exclusive right to screen the Aromatic Polyketides for any biological activity in any biological test system for any therapeutic indication.

For the Research Licenses to the Institute Licensee, Licensor grants the Institute Licensee a non-exclusive license, with no right to grant sublicenses, under Licensor Patent Rights  and Know-how to make and use methods and materials to carry, out the Research Program during the Research Term.

For the Screening Licenses, Licensor grants to the Institute Licensee the non-transferable licenses, with the right to grant sublicenses to the Institute Licensee Affiliates, under the Licensor Patent Rights and Know-how to conduct screening, an exclusive, worldwide license during the exclusive screening period to use the Macrolides, to conduct screening for Antibiotic Activity;

– a non-exclusive, worldwide license during the non-exclusive screening period (a) to use the Macrolides to conduct screening for Antibiotic Activity; (b) to use the Aromatic Polyketides to conduct screening for any activity; and

– a non-exclusive, worldwide license during the Exclusive Screening Period and Non-exclusive screening period to use the Macrolides to conduct screening for activities other than Antibiotic Activity, excluding any right to screen the Macrolides for Motilide or Anti-inflammatory Activity.

For the Development and Commercialization License Grant, Licensor grants to Licensee a worldwide, exclusive license, with the right to grant sublicenses, under the Licensor patent rights and know-how, to make, use and develop Licensed Compounds, and, to make, have made, use, import, offer for sale, sell and have Sold Products.

License Property
The Licensed Compound shall mean a particular Macrolide or Aromatic Polyketide, as the case may be, with respect to which the Institute Licensee has provided a Designated Notice and acquired an exclusive license. For purposes of this Agreement, each Close Structure Analog of any such Licensed Compound shall also be deemed to be a Licensed Compound.

Macrolides shall mean 14-membered macrolactones, such as erythromycin, their 3-ketolide congeners, 12-membered macrolactones, 15-membered and 16-membered macrolactones, and other macrolactones or ketolide congeners agreed by the Joint Committee, in each case, obtained by expression of genes from, polyketide, synthase gone clusters including, but not limited to, the erythromycin, rapamycin, tylosin, candicidin, picromycin, or oleandomycin] polyketide, synthase gene clusters, in each case, which are actually utilized in connection with the Research Program that exist in Licensors proprietary compound library as of the effective date; or are synthesized or acquired by or on behalf of Licensor or Licensee in connection with the Research Program.

Motilide Activity shall mean motilin receptor agonist or antagonist activity.

Product shall mean any pharmaceutical product containing a Licensed Compound or a Derivative thereof which is selected for Development and/or marketing by Licensee or its Affiliates or Subllicensees.

Field of Use
Field shall mean the treatment of bacterial infections for all human and animal pharmaceutical applications.

IPSCIO Record ID: 266847

License Grant
The Parties enter this agreement to collaborate to identify novel molecules derived from Licensor Technology that demonstrate efficacy against assays that are designed to identify compounds having antibacterial or antifungal properties.

Licensor grants an exclusive, worldwide license under the Licensor Technology to the Compound Set to the extent necessary or useful to develop, make, have made, use, sell, offer for sale and import Products in the Territory and within the Field.   This License also includes the right to identify and develop new compounds that are Compound Derivatives of members of such a Compound Set by medicinal chemistry.

Licensor grants a non-exclusive worldwide license to use a Licensor microbial strain and an exclusive,  worldwide license to genes, in each case, solely to manufacture or have manufactured a Compound or Product in the Territory and within the Field, provided such strain and genes direct the synthesis of a compound included within a Compound Set or a Product and were identified or otherwise known or available as part of the R&D Program prior to the expiration of the research period, or, with respect to those Compound Sets opted to be carried into the six month period, were identified or otherwise known or available as part of the R&D Program prior to the expiration of such six month period; and provided further that such licenses shall not include any rights to genetically modify any strains or genes.

Licensor grants a nonexclusive, perpetual license to practice any and all Program Inventions that are not covered by Compound Patents (or applications related thereto, so long as such applications are being prosecuted) made by Licensee employees or consultants, either alone or jointly with Licensor employees or consultants, and assigned to Licensor for any purpose, and a nonexclusive, perpetual license to practice any and all Program Inventions made by Licensee employees or consultants either alone or jointly with Licensor employees or consultants, for Licensee to carry out its responsibilities in accordance with this Agreement.

License Property
Licensor has developed proprietary technologies for the rapid discovery, development and optimization of Compounds.

Compound Set shall mean, with respect to a particular Compound, such Compound and all Compound Derivatives with respect to such compound.  A Compound Set shall not include any Excluded Compound.

Excluded Compound shall mean any chemical compound with respect to which Licensor has granted rights or an option to obtain rights to a Third Party.

Field of Use
Field shall mean use in the treatment, prevention or diagnosis of a fungal or bacterial infection in humans.

Under the terms of this agreement, the companies planned to collaborate to identify and develop novel drugs derived from Licensee's recombinant natural product libraries that demonstrate antibacterial or antifungal properties.

IPSCIO Record ID: 223156

License Grant
For the Research License for DirectedDiversity Technology, Licensor grants a world-wide, nonexclusive, non- cancelable license under the Licensor DirectedDiversity Technology and Licensor Patents to evaluate the Custom Accessible Libraries, DuPont Custom Accessible Libraries and Licensor Accessible Libraries to identify Target Leads pursuant to the Research Program.

For the Background License in the Field for Active Compounds,  Licensor grants a world-wide, nonexclusive license, with the right to sublicense, under any Custom Accessible Library, Licensor Accessible Library, Licensor Patents or Research Program Patents to the extent that such rights are reasonably necessary for the synthesis or commercialization of Active Compounds in the Field.

Licensor grants rights to screen such compounds against Targets outside of the Field.

License Property
The Licensor DirectedDiversity Technology means 3DP Patents and know-how that relate to generating and utilizing a DirectedDiversity Chemical Library, including but not limited to patents for the System, method, and computer program for at least partially automatically generating chemical compounds having desired properties. This term also includes any discoveries, improvements, inventions and modifications made in the Research Program to the extent that they relate to Licensor DirectedDiversity Technology.

Active Compound means any composition of matter that has been shown to have Protease Inhibition and In Vivo Inhibition activity in the course of the Research Program.

The Custom Accessible Libraries means any DirectedDiversity Chemical Library derived from using Licensor DirectedDiversity Technology and structure activity data provided by Licensee, and includes synthetically accessible compounds generated by Licensor and Licensee in the course of the Research Program derived from any source other than Licensee Compounds or a Licensee Compound Library or the Available Chemicals Directory.

The DirectedDiversity Chemical Library means a computer-generated library of compounds containing integrated structure-activity and synthesis data.

Target means the Photosystem II D1 protease.

Licensor Accessible Libraries means any DirectedDiversity Chemical Library that is generated by Licensor outside of the Research Program.

Licensor Compounds means any compounds that are developed by Licensor outside of the Research Program, including but not limited to compounds that are actually synthesized by Licensor or contained in a Licensor Accessible Library.

Field of Use
The Field means the agricultural use of Active Compounds to inhibit the Target and is for the control of pests and disease.

IPSCIO Record ID: 227243

License Grant
Screening License  Licensor hereby grants to Licensee (a) a nonexclusive, worldwide, royalty-free license (without the right to sublicense) to test Licensor Compounds delivered prior to the Effective Date against Targets in the Field and to perform other analytical work on such Licensor Compound (b) a nonexclusive, worldwide, royalty-free license (without the right to sublicense) to test Licensor Compounds delivered after the Effective Date against Targets in the Animal Health Field, Human Therapeutics Field, and Nutrition Field (but not the Agrochemical Field) and to perform other analytical work on such Licensor Compounds, and ( c ) an exclusive (including to the exclusion of Licensor), worldwide, royalty-free license (without the right to sublicense) to test any Directed Array Compounds for significant functional activity against Targets in the Field and to perform other analytical work on Directed Array Compound.

Commercialization Licenses  Licensor hereby grants to Licensee. under Licensor Patent Rights, Licensors interest in any Joint Patent Rights and Licensor Technology, an exclusive (including to the exclusion of Licensor), worldwide, royalty-bearing license (with the right to grant sublicenses, including sublicenses to those Primary Affiliates designated by Licensee) (i) to develop (including the making of Derivative Compounds), have developed, make, or have made Royalty-Bearing Products incorporating or using any patent or other intellectual property rights of Licensor covering the composition, manufacture or use of Licensed Compounds for use, distribution and sale in the Field, and (ii) to distribution for sale and sell in the Field Royalty-Bearing Products incorporating or using any patent or other-intellectual property rights of Licensor covering the composition, manufacture or use of Licensed Compounds, and (iii) to use in the Field Royalty-Bearing Products incorporating or using any patent or other intellectual property rights of Licensor covering the composition, manufacture or use of Licensed Compound.

License Property
Licensor compound shall mean any chemical molecule that is synthesized by Licensor using its proprietary technology and provided by Licensor to Licensee under the Mapping Array Program, or as part of a Compass Array library.

Directed Array(TM) compound means any Licensor Derivative Compound or Licensee Derivative Compound that was synthesized by Licensor under the Directed Array Program.

Array shall mean a set of samples of structurally related chemical compounds arranged in a format such as a microtiter screening plate or another format as mutually agreed to by the Parties.

Licensed compound shall mean (i) all Directed Array Compounds, (ii) any Licensor Compound that the Research Committee designated as a Licensed Compound under the Prior Agreement, and (iii) any Licensor Compound that the Research Committee has designated as a Licensed Compound as provided.

Field of Use
Field means, collectively, the Agrochemical Field, the Human Therapeutics Field, the Nutrition Field, and the Animal Health Field.

Human Therapeutics Field means human therapeutic applications. Agrochemical Field means all agricultural and in planta applications. Nutrition Field means human nutrition applications.

Animal Health Field means animal health applications.

IPSCIO Record ID: 249765

License Grant
For the License to Licensed Products,  Licensor grants an exclusive, even as to Licensor, right and license in the Territory and within the Field under the Licensor Patent Rights and to use the Licensor Know-How to make, have made, use, distribute, promote, market, offer for sale, sell, import and export Licensed Products.

For License to Compounds, Licensor grants an exclusive, even as to Licensor, right and license in the Territory and within the Field under the Licensor Patent Rights and to use the Licensor Know-How to research, develop, make, have made, import, export and use the Selected Compounds, and Active Compounds, Improved Active Compounds and Preliminary Compounds of the same Chemotype as such Selected Compounds, Designated Compounds and Derivative Compounds, for research purposes and to develop Licensed Products.

This agreement also includes non-exclusive grants for research.

License Property
Licensor has certain technology and knowhow, including screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Preliminary Compound means any Compound identified as having binding activity when tested against a Target pursuant to the Screening Program and which has Kd values of 10 micromolar or less (i.e., Kd ~ 1 OµM) or such other binding affinity threshold for a specific Target as shall be agreed upon by the parties in writing.

ALIS means the Automated Ligand Identification System, an automated, ultrahigh throughput ligand selection system proprietary to Licensor that is used to identify multiple classes of chemical ligands against a target protein.

OSCD means Quantisized Surface Complimentary Diversity, a model proprietary to Licensor, in terms of which discrete chemical compliments to the surfaces of a Target are defined.

Licensor Know-How means all proprietary information, data and know-how relating to the NeoMorph Screening Library, NeoMorph Focused Libraries, NeoMorph Chemistry, ALIS, QSCD, the Compounds, Active Compounds, approved Active Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or Licensed Products together with, where applicable, any analogs, derivatives or fragments thereof.

Chemotype means a family or group of Compounds closely structurally related to one or more Active Compounds.

Field of Use
The Field means the treatment or prevention of any disease or condition in humans or animals.

Licensee is interested in identifying potential pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

IPSCIO Record ID: 223155

License Grant
For the Research Program License for Licensor Technology, Licensor hereby grants to German Licensee a worldwide, non-exclusive, irrevocable license under the Licensor Technology during the term of the Research Program to conduct the Research Program.

For Other Licensor Patents, Licensor grants to Licensee irrevocable worldwide, exclusive license in the Field under such patent to make, have made, use, sell, have sold, import and have imported licensed Products, under the conditions stipulated in Article 6, provided that 3DP is not contractually prohibited from granting such an exclusive license.

For ThermoFluor Protein Characterization and Screening Technology, Licensor also grants to Licensee a nonexclusive license under the Licensor Technology to utilize the ThermoFluor Protein Characterization and Screening Technology within the Field also outside of the Research Program.

License Property
The Licensor Technology means patents for System, method, and computer program product for at least partially automatically generating chemical compounds with desired properties from a list of potential chemical compounds to synthesize, and, associated know-how and other intellectual property rights of Licensor that cover the use of DirectedDiversity Accessible Compound Libraries, DirectedDiversity Software Tools and ThermoFluor Protein Characterization and Screening Technology, and other related technology developed by Licensor during the course of this Agreement.

Licensed Product means any commercial product comprising of an Active Compound or a Research Program Compound or a compound synthesized by Licensee and covered by a Compound Patent, provided that the compound synthesized by Licensee results from Optimization Synthesis performed at Licensor on an Active Compound selected for optimization by Licensor.

The Probe library is the collection of discrete, structurally diverse small organic molecules synthesized at the Effective Date from the Accessible Compound Libraries, including additional compounds synthesized subsequently.

The Research Program Compound is a compound that has been synthesized by Licensor in the course of the Research Program, e.g., in the course of optimizing an Active Compound.

Field of Use
The Field means plant management, pest management, including fungi, and animal health, including but not limited to the use of herbicides, plant trait modifiers, plant growth regulators, pesticides, fungicides, animal health care, home and garden products, and environmental health products.  The term Field expressly excludes human diagnostic and human therapeutic products.

IPSCIO Record ID: 249722

License Grant
Licensor grants a worldwide right and license, without the right to sub license, within the Territory, to use the Licensor Intellectual Property and Patent Rights and the Program Intellectual Property owned by Licensor, in each case with application to the Field to the extent necessary or useful to research, develop, have developed, make, have made, use, distribute, promote, market, offer for sale, sell, have sold, import and export Designated Compounds, Derivative Compounds thereof, Products and Shared Products and, Independent Compounds, Derivative Compounds thereof and Independent Products.

This agreement also contains non-exclusive grants for research.

License Property
Licensor has certain technology and know-how, including screening processes and libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Derivative Compounds means any analogs, homologs or isomers of a Designated Screening Compound, a Designated Shared Compound and/or an Independent Compound, as applicable. Designated Compounds means Designated Screening Compounds and Designated Shared Compounds.

Licensor Intellectual Property means, individually and collectively,
(a) all Inventions that are conceived, discovered, developed, generated, created, made or reduced to practice or tangible medium of expression solely by employees or consultants of Licensor at any time prior to the Effective Date, or after the Effective Date if such Inventions are not based upon or related to the performance of the Program;
(b) any tangible materials provided by Licensor to Licensee for use in the conduct of the Program, together with, where applicable, any analogs, derivatives, fragments, progeny, sub-cellular constituents or expression products thereof; and
( c) the NeoMorph Screening Library, ALIS and QSCD.
The term Licensor Intellectual Property, however, does not include any techniques, methodologies, know-how, information and data which is, as of the Effective Date, or later becomes, generally available to the public, other than such techniques, methodologies, know-how, information and data included in Licensor Patent Rights.

NeoMorph Screening Library means the entire collection of libraries consisting of mass-encoded small molecule organic compounds owned by Licensor and developed with NeoMorph Chemistry, comprising approximately ten million (10,000,000) different compounds.

ALIS means the Automated Ligand Identification System, an automated, ultra-high throughput ligand selection system proprietary to Licensor that is used to identify multiple classes of chemical ligands against a target protein.

QSCD means Quantized Surface Complimentary Diversity, a model proprietary to Licensor, pursuant to which discrete chemical compliments to the surfaces of a Target are defined.

Field of Use
Field means all preventative, therapeutic and diagnostic uses in humans.

IPSCIO Record ID: 148361

License Grant
Licensor grants to Licensee
– the sole and exclusive worldwide right and license, with no right to sublicense under both the Licensors Technology and interest in any Joint Technology,  to use the Licensor Transporters for the identification   and/or development  of Lead Compounds and Collaboration Products in the Field of Use;

– the sole and exclusive worldwide right and license,  with the right to sublicense to Affiliates of Licensee and/or one or more Third Parties,  under both the Licensor Technology and interest in any Joint Technology,  to make, have made, use, import,  market,  offer for sale and sell Lead Compounds and Collaboration Products in the Field of Use;

– during the term of the Research Program, the sole and exclusive right and license, with no right to sublicense, under both the Licensor Ancillary Transporter Technology and interest in any Joint Technology,  to use the Licensor Ancillary Transporters  for the sole purpose of conducting selectivity testing of Lead Compounds and Collaboration Products;

– after the term of the Research Program, a non-exclusive right and license,  with no right to sublicense,  under the Licensor Ancillary Transporter Technology to use the Licensor  Ancillary Transporters for the sole purpose of conducting selectivity testing of Lead Compounds and Collaboration Products;

– during the term of this Agreement, a nonexclusive right and license, with no right to sublicense, to use all data and information generated by or on behalf of Licensor in the conduct of the Research  Program,  including data relating to Hits in the Licensor Proprietary Chemical Library, but only as shall be reasonably  necessary for Licensee to conduct research to identify and develop Lead Compounds and   Collaboration Products,  provided,  however,  that such license shall become sole and exclusive when a  Compound is designated a Lead Compound in accordance  with Article Six and shall revert to a non-exclusive  license  upon  determination  of  the  Steering Committee or  Licensee  that such Lead  Compound will not become a Collaboration Product;

– during the term of this Agreement, an exclusive right and license,  with the right to sublicense,  to use all data and information generated by or on behalf of Licensor in the conduct of the  Research Program  relating to Lead Compounds and/or Collaboration Products in the Licensor Proprietary Chemical Library,  but only as shall be reasonably necessary for Licensee to conduct research to identify and develop Lead Compounds and Collaboration Products; and

– during the term of this Agreement,  a non-exclusive right and license,  with no right to sublicense, to use the Licensor Materials but only to the extent that such right and license shall be necessary for Licensee to identify and develop Lead Compounds and Collaboration Products.

License Property
Licensor is the owner or licensee of certain patent rights relating to human glutamate transporters.

Glutamate transporters are a family of neurotransmitter transporter proteins that move glutamate – the principal excitatory neurotransmitter – across a membrane.

Licensor Transporters mean EAAT-2 and EAAT-3  protein of amino-acid compositions.

Field of Use
The field means all therapeutic, prophylactic and diagnostic uses.

IPSCIO Record ID: 222558

License Grant
For the Compounds and Products, Licensor grants an exclusive license under the Licensor Technology and Licensors interest in the Collaboration Technology, exclusive even as to Licensor and its Affiliates, to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory. It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.

For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to  Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.

For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each  grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows  the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.

For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.

License Property
Licensor has developed proprietary technologies relating to the design and preparation of encoded compound libraries based upon combinatorial chemistry.  'Licensor Technology' shall mean Existing Licensor Patent Rights, Existing Licensor Know-How, and Licensor Improvements (with some exceptions).

Product means any Agreement Product or Licensees Product.

Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.

Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.

Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.

Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'

Field of Use
This agreement field relates to assays, compound screening methods and biological research tools used to design, prepare and screen compound libraries against Licensees biological targets.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.